Msd Sub Merck patents expiration
1. Bridion patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE44733 | MSD SUB MERCK | 6-mercapto-cyclodextrin derivatives:reversal agents for drug-induced neuromuscular block |
Jan, 2026
(1 year, 8 months from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7265099 | MSD SUB MERCK | Use of chemical chelators as reversal agents for drug-induced neuromuscular block |
Aug, 2020
(3 years ago) | |
| US7265009 | MSD SUB MERCK | HDP-CVD methodology for forming PMD layer |
Aug, 2020
(3 years ago) | |
| US6949527 | MSD SUB MERCK | 6-Mercapto-cyclodextrin derivatives: reversal agents for drug-induced neuromuscular block |
Jan, 2021
(3 years ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Jun 25, 2024 |
| M(M-291) | Jan 22, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 15, 2020 |
| M(M-262) | Jun 09, 2023 |
Drugs and Companies using SUGAMMADEX SODIUM ingredient
NCE-1 date: 16 December, 2019
Market Authorisation Date: 15 December, 2015
Treatment: Reversal of neuromuscular blockage induced by rocuronium bromide or vecuronium bromide; Reversal of drug-induced neuromuscular block
Dosage: SOLUTION;INTRAVENOUS
BRIDION family patents
2. Integrilin patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5756451 | MSD SUB MERCK | Platelet aggregation inhibitors |
Nov, 2014
(9 years ago) | |
| US5686570 | MSD SUB MERCK | Platelet aggregation inhibitors |
Nov, 2014
(9 years ago) | |
| US5747447 | MSD SUB MERCK | Stable polypeptide composition |
May, 2015
(8 years ago) | |
| US5968902 | MSD SUB MERCK | Platelet aggregation inhibitors |
Jun, 2015
(8 years ago) | |
| US5807825 | MSD SUB MERCK | Platelet aggregation inhibitors |
Sep, 2015
(8 years ago) | |
Drugs and Companies using EPTIFIBATIDE ingredient
Market Authorisation Date: 18 May, 1998
Treatment: Treatment of platelet associated ischemic disorders; Platelet aggregation inhibitors
Dosage: INJECTABLE;INJECTION
INTEGRILIN family patents
3. Invanz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5652233 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(11 years ago) | |
| US5478820 | MSD SUB MERCK | Antibiotic compounds |
Nov, 2015
(8 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7342005 | MSD SUB MERCK | Antibiotic compounds |
Feb, 2013
(11 years ago) | |
|
US7342005 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(10 years ago) | |
|
US5652233 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
Aug, 2013
(10 years ago) | |
|
US5478820 (Pediatric) | MSD SUB MERCK | Antibiotic compounds |
May, 2016
(7 years ago) | |
| US5952323 | MSD SUB MERCK | Carbapenem antibiotic |
May, 2017
(6 years ago) | |
|
US5952323 (Pediatric) | MSD SUB MERCK | Carbapenem antibiotic |
Nov, 2017
(6 years ago) | |
Drugs and Companies using ERTAPENEM SODIUM ingredient
Market Authorisation Date: 21 November, 2001
Treatment: Treatment of bacterial infectious disease
Dosage: INJECTABLE;INTRAMUSCULAR, INTRAVENOUS
INVANZ family patents
4. Isentress patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months ago) | |
| US8852632 | MSD SUB MERCK | Pharmaceutical formulation containing a release rate controlling composition |
Jan, 2028
(3 years from now) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 9 days ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 9 days ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(26 days ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Nov 22, 2020 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| New Dosage Form(NDF) | Dec 21, 2014 |
| M(M-114) | Mar 28, 2015 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
Market Authorisation Date: 21 December, 2011
Treatment: Treatment of hiv infection
Dosage: TABLET, CHEWABLE;ORAL; POWDER;ORAL; TABLET;ORAL
ISENTRESS family patents
5. Isentress Hd patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7169780 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(6 months ago) | |
| US7754731 | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(4 years from now) | |
| US8771733 | MSD SUB MERCK | Pharmaceutical composition containing an anti-nucleating agent |
Jun, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7435734 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
| US7217713 | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(1 year, 6 months ago) | |
|
US7217713 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 9 days ago) | |
|
US7435734 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(1 year, 9 days ago) | |
|
US7169780 (Pediatric) | MSD SUB MERCK | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(26 days ago) | |
|
US7754731 (Pediatric) | MSD SUB MERCK | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(5 years from now) | |
| US9649311 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(6 years from now) | |
|
US9649311 (Pediatric) | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(6 years from now) | |
| US10772888 | MSD SUB MERCK | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Strength(NS) | May 26, 2020 |
| New Dosing Schedule(D-167) | May 26, 2020 |
| New Patient Population(NPP) | Dec 21, 2014 |
| Pediatric Exclusivity(PED) | May 22, 2021 |
| M(M-114) | Mar 28, 2015 |
| New Chemical Entity Exclusivity(NCE) | Oct 12, 2012 |
Drugs and Companies using RALTEGRAVIR POTASSIUM ingredient
NCE-1 date: 22 May, 2020
Market Authorisation Date: 12 October, 2007
Treatment: Integrase inhibition for the treatment of hiv infection; Treatment of hiv infection; Treatment of hiv-1 infection
Dosage: TABLET;ORAL
ISENTRESS HD family patents
6. Janumet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6303661 | MSD SUB MERCK | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7125873 | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
|
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US7125873 (Pediatric) | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| US8414921 | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jul, 2028
(4 years from now) | |
|
US8414921 (Pediatric) | MSD SUB MERCK | Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin |
Jan, 2029
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Jun 04, 2024 |
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2011 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 05 June, 2023
Market Authorisation Date: 30 March, 2007
Treatment: Improvement of glycemic control in adults with type 2 diabetes mellitus; Method of treating type 2 diabetes mellitus by administering a dipeptidyl peptidase-iv inhibitor in combination with metformin;...
Dosage: TABLET;ORAL
JANUMET family patents
7. Janumet Xr patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6340475 | MSD SUB MERCK | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6635280 | MSD SUB MERCK | Extending the duration of drug release within the stomach during the fed mode |
Sep, 2016
(7 years ago) | |
| US6303661 | MSD SUB MERCK | Use of dipeptidyl peptidase IV effectors for lowering the blood glucose level in mammals |
Apr, 2017
(7 years ago) | |
| US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7125873 | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
|
US7125873 (Pediatric) | MSD SUB MERCK | Beta-amino tetrahydroimidazo (1, 2-a) pyrazines and tetrahydrotrioazolo (4, 3-a) pyrazines as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-187) | Dec 04, 2023 |
| Pediatric Exclusivity(PED) | Feb 12, 2023 |
| M(M-244) | Aug 12, 2022 |
Drugs and Companies using METFORMIN HYDROCHLORIDE; SITAGLIPTIN PHOSPHATE ingredient
Market Authorisation Date: 02 February, 2012
Treatment: Improvement of glycemic control in adults with type 2 diabetes mellitus; Method of treating type 2 diabetes mellitus in patients for whom treatment with both sitagliptin and metformin hcl extended rel...
Dosage: TABLET, EXTENDED RELEASE;ORAL
JANUMET XR family patents
8. Segluromet patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| US9439902 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; METFORMIN HYDROCHLORIDE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
SEGLUROMET family patents
9. Steglatro patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: An adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
Dosage: TABLET;ORAL
STEGLATRO family patents
10. Steglujan patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US6699871 | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jul, 2022
(1 year, 9 months ago) | |
| US7326708 | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
Nov, 2026
(2 years from now) | |
| US8080580 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Jul, 2030
(6 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7078381 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US6890898 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
| US7459428 | MSD SUB MERCK | Method of regulating glucose metabolism, and reagents related thereto |
Feb, 2019
(5 years ago) | |
|
US6699871 (Pediatric) | MSD SUB MERCK | Beta-amino heterocyclic dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes |
Jan, 2023
(1 year, 3 months ago) | |
|
US7326708 (Pediatric) | MSD SUB MERCK | Phosphoric acid salt of a dipeptidyl peptidase-IV inhibitor |
May, 2027
(3 years from now) | |
| US9439901 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| US9308204 | MSD SUB MERCK | Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives |
Oct, 2030
(6 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-275) | Sep 17, 2024 |
| New Chemical Entity Exclusivity(NCE) | Dec 19, 2022 |
Drugs and Companies using ERTUGLIFLOZIN; SITAGLIPTIN PHOSPHATE ingredient
NCE-1 date: 19 December, 2021
Market Authorisation Date: 19 December, 2017
Treatment: Ertugliflozin and sitagliptin in combination as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus; Ertugliflozin in combination with sitagliptin and i...
Dosage: TABLET;ORAL
STEGLUJAN family patents
11. Zepatier patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7973040 | MSD SUB MERCK | Macrocyclic quinoxaline compounds as HCV NS3 protease inhibitors |
Jul, 2029
(5 years from now) | |
| US8871759 | MSD SUB MERCK | Inhibitors of hepatitis C virus replication |
May, 2031
(7 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Patient Population(NPP) | Dec 09, 2024 |
| New Chemical Entity Exclusivity(NCE) | Jan 28, 2021 |
Drugs and Companies using ELBASVIR; GRAZOPREVIR ingredient
NCE-1 date: 29 January, 2020
Market Authorisation Date: 28 January, 2016
Treatment: Treatment of patients infected with hepatitis c virus
Dosage: TABLET;ORAL
ZEPATIER family patents
12. Zolinza patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| USRE38506 | MSD SUB MERCK | Potent inducers of terminal differentiation and methods of use thereof |
Jul, 2015
(8 years ago) | |
| US7456219 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2027
(2 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8067472 | MSD SUB MERCK | Methods of treating Hodgkin's and non-Hodgkin's lymphoma |
Mar, 2023
(1 year, 1 month ago) | |
| US8101663 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(1 year, 1 month ago) | |
| US7652069 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Mar, 2023
(1 year, 1 month ago) | |
| US7732490 | MSD SUB MERCK | Methods of treating cancer |
Mar, 2023
(1 year, 1 month ago) | |
| US7851509 | MSD SUB MERCK | Polymorphs of suberoylanilide hydroxamic acid |
Feb, 2024
(2 months ago) | |
| US7399787 | MSD SUB MERCK | Methods of treating cancer with HDAC inhibitors |
Feb, 2025
(9 months from now) | |
| US8093295 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing the same |
May, 2026
(2 years from now) | |
| US8450372 | MSD SUB MERCK | Formulations of suberoylanilide hydroxamic acid and methods for producing same |
Mar, 2028
(3 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 06, 2011 |
| Orphan Drug Exclusivity(ODE) | Oct 06, 2013 |
Drugs and Companies using VORINOSTAT ingredient
NCE-1 date: 06 October, 2010
Market Authorisation Date: 06 October, 2006
Treatment: Treatment of cutaneous manifestations in patients with cutaneous t-cell lymphoma (ctcl)
Dosage: CAPSULE;ORAL
ZOLINZA family patents